Epidermal growth factor receptor expression in anal canal carcinoma

American Journal of Clinical Pathology

Volumn 124, Issue 1, 2005, Pages 20-23

  Lê, Lyly H ^a   Chetty, Runjan ^b   Moore, Malcolm J ^b  

^a Fraser Valley Cancer Centre   (Canada)

^b PRINCESS MARGARET HOSPITAL   (Canada)

Author keywords

Anal canal carcinoma; Basaloid; Epidermal growth factor receptor; Squamous cell

Indexed keywords

ANTIINFECTIVE AGENT; EPIDERMAL GROWTH FACTOR RECEPTOR;

ADULT; AGED; ANUS CARCINOMA; CELL CYCLE; CELL SURFACE; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN TISSUE; MALE; MEDICAL LITERATURE; ONCOGENE NEU; PRIORITY JOURNAL; RECTUM ABDOMINOPERINEAL RESECTION; REVIEW; SQUAMOUS CELL CARCINOMA; TUMOR BIOPSY; TUMOR GROWTH;

EID: 21744460025     PISSN: 00029173     EISSN: None     Source Type: Journal    
DOI: 10.1309/X4UADHVN317V2XMW     Document Type: Review

References (18)

1. Reis LAG, Eisner MP, Kosary CL, et al, eds. SEER Cancer Statistics Review, 1975-2001. Bethesda, MD: National Cancer Institute. Available at http://seer.cancer.gov/csr/1975_2001. Accessed September 2004.
2. Clark MA, Hartley A, Geh JI. Cancer of the anal canal. Lancet Oncol 2004;5:149-157.
3. El-Rayes BF, LoRusso PM. Targeting the epidermal growth factor receptor. Br J Cancer. 2004;91:418-424.
4. Condon LT, Ashman JN, Ell SR, et al. Overexpression of bcl-2 in squamous cell carcinoma of the larynx: a marker of radioresistance. Int J Cancer. 2002;100:472-475.
5. Nagy B, Tiszlavicz L, Eller J, et al. Ki-67, cyclin D1, p53 and bcl-2 expression in advanced head and neck cancer. In Vivo. 2003;17:93-96.
6. Shintani S, Mihara M, Ueyama Y, et al. Cyclin D1 overexpression associates with radiosensitivity in oral squamous cell carcinoma. Int J Cancer. 2001;96:159-165.
7. Wang MB, Yip HT, Srivatsan ES. Antisense cyclin D1 enhances sensitivity of head and neck cancer cells to cisplatin. Laryngoscope. 2001;111:982-988.
8. Vielba R, Bilbao J, Ispizua A, et al. p53 and cyclin D1 as prognostic factors in squamous cell carcinoma of the larynx. Laryngoscope. 2003;113:167-172.
9. Indinnimeo M, Cicchini C, Stazi A, et al. Prognostic impact of CD31 antigen expression in anal canal carcinoma. Hepatogastroenterology. 2001;48:1355-1358.
10. Holm R, Skovlund E, Skomedal H, et al. Reduced expression of p21WAF1 is an indicator of malignant behaviour in anal carcinomas. Histopathobgy. 2001;39:43-49.
11. Indinnimeo M, Cicchini C, Stazi A, et al. Immunohistochemical assessment of Ki-67 as prognostic cellular proliferation marker in anal canal carcinoma. J Exp Clin Cancer Res. 2000;19:471-475.
12. Perez-Soler R, Chachoua A, Hammond LA, et al. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol. 2004;22:3238-3247.
13. Giaccone G, Herbst RS, Manegold C, et al. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 1. J Clin Oncol. 2004;22:777-784.
14. Herbst RS, Giaccone G, Schiller JH, et al. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial: INTACT 2. J Clin Oncol. 2004;22:785-794.
15. Soulieres D, Senzer NN, Yokes EE, et al. Multicenter phase II study of erlotinib, an oral epidermal growth factor receptor tyrosine kinase inhibitor, in patients with recurrent or metastatic squamous cell cancer of the head and neck. J Clin Oncol. 2004;22:77-85.
16. Rich JN, Reardon DA, Peery T, et al. Phase II trial of gefitinib in recurrent glioblastoma. J Clin Oncol. 2004;22:133-142.
17. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129-2139.
18. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497-1500.